Cambridge Biotech Corp. on Tuesday said it has signed acollaborative research agreement with the Walter Reed ArmyInstitute of Research to evaluate potential malaria vaccines.

The initial agreement, for six to nine months, is for Phase Ianimal trials. The trials will test Cambridge's Stimulon saponinadjuvant (immunostimulant) with recombinant antigenssupplied by Walter Reed. Saponin is a compound derived fromthe bark of Quillaja saponaria molina.

In exchange for a nominal sum to supply the animals,Cambridge retains the right to commercialize Stimulon inmalaria vaccines. If the adjuvant works, the U.S. Army has theright to a royalty-free license for Stimulon for its own use only.

Ribi ImmunoChem Research Inc.'s Detox adjuvant is in Phase IIclinical trials against malaria being conducted by Ribi,SmithKline Beecham and the U.S. Army and Navy. The resultsof the Phase I study, published in the April 27 issue of TheLancet, show that Detox works at least 10 times as well as alumin promoting a response to malaria vaccines. Alum is the onlyapproved adjuvant.

Cambridge, based in Worcester, Mass., in 1990 received U.S.Department of Agriculture approval to market its felineleukemia vaccine containing Stimulon.

Cambridge stock (NASDAQ:CBCX) closed at $5.13 on Tuesday, up13 cents. Ribi stock (NASDAQ:RIBI) closed down 13 cents at$4.13.

(c) 1997 American Health Consultants. All rights reserved.